| |
 
| |
 |
| |
|
|
| |
Profile |
|
| |
|
|
| |
is a leader in the discovery and development of novel, small molecule pharmaceuticals. The company has utilized its proprietary discovery platform to develop a portfolio of clinical and preclinical stage programs in a number of therapeutic areas, including metabolic disease, oncology, CNS, inflammation and cardiovascular disease.
Plexxikon's unique discovery approach, combined with an experienced management and scientific team, a broad network of scientific and clinical experts, and creative partnering, have been key drivers of the company's success since it began operations in 2001.
With its Scaffold-Based Drug Discovery Platform™, Plexxikon uses compound and target structural data to guide chemistry early in the drug lead generation process within various families of drug targets. This systematic, cost-efficient approach allows Plexxikon to leverage its chemistry investment in any one drug target for other targets within that family. This strategy has resulted in a comprehensive portfolio and pipeline of opportunities for both its internal and partnered programs.
 Product Pipeline pdf
Corporate Fact Sheet |
|
| |
|
|
|
|
 |
|
|
| |
| |
|
| |
|
|
| |
Profile |
|
| |
|
|
| |
is a leader in the discovery and development of novel, small molecule pharmaceuticals. The company has utilized its proprietary discovery platform to successfully develop a portfolio of clinical and preclinical stage programs in a number of therapeutic areas, including metabolic disease, oncology, inflammation, CNS and cardiovascular disease.
Plexxikon's unique discovery approach, combined with an experienced management and scientific team, a broad network of scientific and clinical experts, and creative partnering, have been key drivers of the company's success since it began operations in 2001.
With its Scaffold-Based Drug Discovery Platform™, Plexxikon uses compound and target structural data to guide chemistry early in the drug lead generation process within various families of drug targets. This systematic, cost-efficient approach allows Plexxikon to leverage its target-specific chemistry investment for other targets within that family.
Plexxikon’s business strategy is to generate competitively differentiated drug candidates across multiple therapeutic areas, then partner at the IND or early clinical stage for further co-development and commercialization. This has resulted in a comprehensive portfolio and pipeline of opportunities, generating significant value for Plexxikon, its collaborators and investors.
Product Pipeline
Corporate Fact Sheet |
|
| |
|
|
|
|
|
| |
| | | | | | |
| | | | | | | | |
| © 2007 Plexxikon Inc. | Site design by |
| |
|
|